Triflusal
SIGMA/T6580 - ≥98% (HPLC), powder
Synonym: Triflusal; α,α,α-trifluoro-2,4-cresotic acid acetate; 2-
CAS Number: 322-79-2
Empirical Formula (Hill Notation): C10H7F3O4
Molecular Weight: 248.16
EC Number: 206-297-5
Linear Formula: C10H7F3O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C10H7F3O4/c1-5(14)17-8 |
| InChI key | RMWVZGDJPAKBDE-UHFFFAOYSA |
| originator | Uriach |
| Quality Level | 100 ![]() |
| SMILES string | FC(F)(F)c1cc(c(cc1)C(=O)O |
| solubility | DMSO: >30 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. |
| Biochem/physiol Actions: | Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization. |
| Features and Benefits: | This compound was developed by Uriach . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H317 - H319 - H335 |
| Precautionary statements | P280 - P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38-43 |
| Safety Statements | 26-36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


